The extracellular matrix: Friend or foe in airway disease?

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

Airway remodelling includes thickening of the basement membrane and alterations in the extracellular matrix (ECM) composition. These changes play a key role in the pathogenesis of a number of pulmonary fibrotic diseases including asthma and chronic obstructive pulmonary disease. Insight into the mechanisms underlying the alterations in ECM in the different pathologies may be gained by comparing the profiles of the changes in the different diseases and understanding the functional outcomes resulting from these changes. Whereas current pulmonary treatment regimens are partially effective in preventing or reversing ECM changes there is an obvious need for development of the next generation of therapeutics targeting the ECM.
Original languageEnglish
Pages (from-to)219-236
Number of pages18
JournalMinerva Pneumologica
Volume49
Issue number4
Publication statusPublished - 1-Dec-2010
Externally publishedYes

Keywords

  • Airway remodelling
  • Extracellular matrix
  • Lung diseases
  • Therapeutics
  • beta 2 adrenergic receptor stimulating agent
  • biglycan
  • collagen type 1
  • collagen type 3
  • collagen type 4
  • collagen type 5
  • decorin
  • dexamethasone
  • elastin
  • fibronectin
  • glucocorticoid
  • heparin
  • hyaluronic acid
  • laminin
  • leukotriene receptor blocking agent
  • lumican
  • montelukast
  • perlecan
  • phosphodiesterase inhibitor
  • proteoglycan
  • roflumilast
  • tenascin
  • versican
  • add on therapy
  • airway remodeling
  • asthma
  • basement membrane
  • bronchiolitis obliterans organizing pneumonia
  • chronic obstructive lung disease
  • smoking
  • corticosteroid therapy
  • drug efficacy
  • drug targeting
  • extracellular matrix
  • functional assessment
  • human
  • inflammation
  • lymphangioleiomyomatosis
  • nonhuman
  • pathogenesis
  • respiratory tract disease
  • review

Cite this